Mild/moderate haemophilia A: New insights into molecular mechanisms and inhibitor development

Haemophilia

Volumn 14, Issue SUPPL. 3, 2008, Pages 138-146

  D'Oiron, Roseline ^a   Pipe, S W ^b   Jacquemin, M ^c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Factor VIII; Genotype; Inhibitor; Mild moderate haemophilia A; T cell epitope

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DESMOPRESSIN; EPITOPE; IMMUNOMODULATING AGENT; PHOSPHOLIPID; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB; VON WILLEBRAND FACTOR;

ARTICLE; BLEEDING; CELL INTERACTION; DISEASE SEVERITY; DRUG INDICATION; ENDOPLASMIC RETICULUM; ERADICATION THERAPY; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MEDICAL DECISION MAKING; MISSENSE MUTATION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; T LYMPHOCYTE; THROMBOCYTE ACTIVATION;

ANTIBODIES; DEAMINO ARGININE VASOPRESSIN; EPITOPES; FACTOR IXA; FACTOR VIII; GENOTYPE; HEMOPHILIA A; HEMORRHAGE; HEMOSTATICS; HUMANS; IMMUNE TOLERANCE; MUTATION, MISSENSE; THROMBIN;

EID: 44249088320     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01730.x     Document Type: Article

References (65)

1. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first twenty years. Haemophilia 2000; 6 (Suppl. 1): 60-67.
2. Kemball-Cook G, Tuddenham EG, Wacey AI. The factor VIII structure and mutation resource site: HAMSTeRS version 4. Nucleic Acids Res 1998; 26: 216-9. Available at http://europium.csc.mrc.ac.uk/ accessed January 2008.
3. Fay PJ, Jenkins PV. Mutating factor VIII: Lessons from structure to function. Blood Rev 2005; 19: 15-27.
4. Shen BW, Spiegel PC, Chang CH et al. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008; 111: 1240-7.
5. Hay CRM, Ludlam CA, Colvin BT et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Thromb Haemost 1998;79: 762-6.
6. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002; 8: 23-29.
7. Fijnvandraat K, Turenhout EAM, van den Brink EN et al. The missense mutation Arg 593 → Cys is related to antibody formation in a patient with mild hemophilia A. Blood 1997; 89: 4371-7.
8. Peerlinck K, Jacquemin M. Inhibitors to factor VIII-mild and moderate hemophilia. In: Lee CA, Berntorp EE, Hoots WK, eds. Textbook of Hemophilia Oxford: Blackwell Publishing, 2005: 71-73.
9. Santagostino E, Gringeri A, Tagliavacca L, Mannucci PM. Inhibitors to factor VIII in a family with mild hemophilia: Molecular characterization and response to factor VIII and desmopressin. Thromb Haemost 1995; 74: 619-21.
10. Franchini M, Girelli D, Olivieri O et al. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A. Haemophilia 2006; 12: 448-51.
11. Thompson AR, Murphy MEP, Liu ML et al. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg 593 to Cys mutation. Blood 1997; 90: 1902-10.
12. Jacquemin M, Lavendhomme R, Benhida A et al. Rupture of tolerance to self factor VIII in mild/moderate hemophilia A. Blood 2004; 104: 11 (abstract 3076).
13. Bril WS, Turenhout EAM, Kaijen PHP et al. Analysis of factor VIII inhibitors in a haemophilia A patient with an Arg 593 →Cys mutation using phage display. Br J Haematol 2002; 119: 393-6.
14. Jacquemin M, Benhida A, Peerlinck K et al. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood 2000; 95: 156-63.
15. van den Brink EN, Timmermans SM, Turenhout EA et al. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg 593 → Cys substitution. Thromb Haemost 1999; 81: 723-6.
16. + T-cell clones specific for wild-type factor VIII: A molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 2003; 101: 1351-8.
17. James EA, Kwok WW, Ettinger RA, Thompson AR, Pratt KP. T-cell responses over time in a mild hemophilia A inhibitor subject: Epitope identification and transient immunogenicity of the corresponding self-peptide. J Thromb Haemost 2007; 5: 2399-407.
18. Bogdanova N, Markoff A, Eisert R et al. Spectrum of molecular defects and mutation detection rate in patients with mild and moderate hemophilia A. Hum Mutat 2007; 28: 54-60.
19. Pipe SW, Kaufman RJ. Structural and functional role of the factor VIII B domain. Haematologica 2004; 89: 8-13.
20. Liu ML, Shen BW, Nakaya S et al. Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood 2000; 96: 979-87.
21. Jacquemin M, Lavend'homme R, Benhida A et al. A novel cause of mild/ moderate hemophilia A: Mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor. Blood 2000; 96: 958-65.
22. Michnick DA, Pittman DD, Wise RJ, Kaufman RJ. Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J Biol Chem 1994; 269: 20095-102.
23. Mumford AD, Laffan M, O'Donnell J et al. A Tyr346->Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy. Br J Haematol 2002; 118: 589-94.
24. Lyall H, Hill M, Westby J, Grimley C, Dolan G. Tyr346->Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype -is this mild haemophilia A? Haemophilia 2008; 14: 78-80.
25. Rudzki Z, Duncan EM, Casey GJ, Neumann M, Favaloro EJ, Lloyd JV. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 1996; 94: 400-6.
26. Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EG, Kemball-Cook G. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997; 89: 2413-21.
27. Schwaab R, Oldenburg J, Kemball-Cook G et al. Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family. Br J Haematol 2000; 109: 523-8.
28. Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost 2003; 29: 23-30.
29. Rodgers SE, Duncan EM, Barbulescu DM, Quinn DM, Lloyd JV. In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results. Br J Haematol 2007; 136: 138-45.
30. Cid AR, Casaña P, Cabrera N, Haya S, Cortina V, Aznar JA. Inhibitor development in one patient and laboratory discrepancies in several families with both mild haemophilia and Arg531Cys mutation. Haemophilia 2007; 13: 206-8.
31. Wakabayashi H, Zhou Q, Varfaj F, Fay PJ. A3 domain residue Glu1829 contributes to A2 subunit retention in factor VIIIa. J Thromb Haemost 2007; 5: 996-1001.
32. Pipe SW, Saenko EL, Eickhorst AN, Kemball-Cook G, Kaufman RJ. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 2001; 97: 685-91.
33. Keeling DM, Sukhu K, Kemball-Cook G, Waseem N, Bagnall R, Lloyd JV. Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954->Leu substitution in the factor VIII A3 domain. Br J Haematol 1999; 105: 1123-6.
34. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402: 439-42.
35. Macedo-Ribeiro S, Bode W, Huber R et al. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature 1999; 402: 434-9.
36. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood 2002; 99: 1215-23.
37. Spiegel PC, Murphy P, Stoddard BL. Surface-exposed hemophilic mutations across the factor VIII C2 domain have variable effects on stability and binding activities. J Biol Chem 2004; 279: 53691-8.
38. Amano K, Sarkar R, Pemberton S, Kemball-Cook G, Kazazian HH Jr, Kaufman RJ. The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII. Blood 1998; 91: 538-48.
39. Jenkins PV, Freas J, Schmidt KM, Zhou Q, Fay PJ. Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex. Blood 2002; 100: 501-8.
40. d'Oiron R, Lavergne JM, Lavend'homme R et al. Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development. Blood 2004; 103: 155-7.
41. Naylor JA, Green PM, Rizza CR, Giannelli F. Analysis of factor VIII mRNA reveals defects in everyone of 28 haemophilia A patients. Hum Mol Genet 1993; 2: 11-17.
42. Knobe KE, Villoutreix BO, Tengborn LI, Petrini P, Ljung RC. Factor VIII inhibitors in two families with mild haemophilia A: Structural analysis of the mutations. Haemostasis 2000; 30: 268-79.
43. Peerlinck K, Jacquemin MG, Arnout J et al. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood 1999; 93: 2267-73.
44. Liu ML, Nakaya S, Thompson AR. Non-inversion factor VIII mutations in 80 hemophilia A families including 24 with alloimmune responses. Thromb Haemost 2002; 87: 273-6.
45. Fernández-López O, García-Lozano JR, Núñez-Vázquez R, Pérez-Garrido R, Núñez-Roldán A. The spectrum of mutations in Southern Spanish patients with hemophilia A and identification of 28 novel mutations. Haematologica 2005; 90: 707-10.
46. Naylor JA, Green PM, Montandon AJ, Rizza CR, Giannelli F. Detection of three novel mutations in two haemophilia A patients by rapid screening of whole essential region of factor VIII gene. Lancet 1991; 337: 635-9.
47. Cutler JA, Mitchell MJ, Smith MP, Savidge GF. The identification and classification of 41 novel mutations in the factor VIII gene (F8C). Hum Mutat 2002; 19: 274-8.
48. Pieneman WC, Deutz-Terlouw PP, Reitsma PH, Briët E. Screening for mutations in haemophilia A patients by multiplex PCR-SSCP, Southern blotting and RNA analysis: The detection of a genetic abnormality in the factor VIII gene in 30 out of 35 patients. Br J Haematol 1995; 90: 442-9.
49. Astermark J, Berntorp E, White GC, Kroner BL, The MIBS Study Group. The MalmöInternational Brother Study (MIBS): Further support for genetic predisposition to inhibitor development. Haemophilia 2001; 7: 267-72.
50. Bril WS, MacLean PE, Kaijen PH et al. HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation. Haemophilia 2004; 10: 509-14.
51. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK, MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
52. Oldenburg J, Schroder J, Brackmann HH, Muller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004; 41 (Suppl. 1): 82-88.
53. White B, Cotter M, Byrne M, O'Shea E, Smith OP. High responding factor VIII inhibitors in mild haemophilia - is there a link with recent changes in clinical practice? Haemophilia 2000; 6: 113-5.
54. Roussel-Robert V, Torchet MF, Legrand F, Rothschild C, Stieltjes N. Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients. J Thromb Haemost 2003; 1: 2450-1.
55. Sharatkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36.
56. von Auer Ch, Oldenburg J, von Depka M et al. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci 2005; 1051: 498-505.
57. Matzinger P. The danger model: A renewed sense of self. Science 2002; 296: 301-5.
58. Robbins D, Kulkarni R, Gera R, Scott-Emuakpor AB, Bosma K, Penner JA. Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy. Am J Hematol 2001; 68: 184-8.
59. Vlot AJ, Wittebol S, Strengers PF et al. Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618->Ser mutation responsive to immune tolerance induction and cyclophosphamide. Br J Haematol 2002; 117: 136-40.
60. Wiestner A, Cho HJ, Asch AS, Michells MA, Zeller JA, Peerschke EIB. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 3426-8.
61. Carcao M, St Louis J, Poon MC et al. Inhibitor Subcommittee of Association of Hemophilia Clinic Directors of Canada. Rituximab for congenital haemophiliacs with inhibitors: A Canadian experience. Haemophilia 2006; 12: 7-18.
62. Dunkley S, Kershaw G, Young G et al. Rituximab treatment of mild haemophilia A with inhibitors: A proposed treatment protocol. Haemophilia 2006; 12: 663-7.
63. Leebeek FWG, Kappers-Klunne MC, Jie KSG. Effective and safe use of recombinant factor VIIa (NovoSeven ®) in elderly mild haemophilia A patients with high-titre antibodies against factor VIII. Haemophilia 2004; 10: 250-3.
64. d'Oiron R, Volot F, Reynaud J et al. Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia A and inhibitors. Semin Hematol 2006; 43: S3-S9.
65. Vanderlugt CJ, Miller SD. Epitope spreading. Curr-Opin-Immunol 1996; 8: 831-6.